Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Menu

Chlorpropamide 250 Mg Tabs 100 By Mylan Pharma

Image 0 of Chlorpropamide 250 Mg Tabs 100 By Mylan PharmaImage 1 of Chlorpropamide 250 Mg Tabs 100 By Mylan Pharma

Chlorpropamide 250 Mg Tabs 100 By Mylan Pharma

Call for Price

Chlorpropamide 250 Mg Tabs 100 By Mylan Pharma This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD2813665/RXB10029980
Size : 100
Selling UoM : EA
NDC: 00378-0210-01
UPC Barcode : 303780210011
Supplier: 0050000337 MYLAN PHARM
Supplier Material : 021001
Generic Code : 001769 CHLORPROPAMIDE ORAL TABLET 250 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : GRX Generic RX

Have a question?

  Call for Price

Product Description.:

MYLAN 210, 250
tablet , green , scored , round round

DIABINESE? (chlorpropamide), is an oral blood-glucose-lowering drug of the sulfonylurea class.

Chlorpropamide is a white crystalline powder, that has a slight odor. It is practically insoluble in water at pH 7.3 (solubility at Ph 6 is 2.2 mg/mL). It is soluble in alcohol and moderately soluble in chloroform. The molecular weight of chlorpropamide is 276.74.

DIABINESE is available as 100 mg and 250 mg tablets.

Inert ingredients are: alginic acid Blue 1 Lake hydroxypropyl cellulose magnesium stearate precipitated calcium carbonate sodium lauryl sulfate starch.

INDICATIONS

DIABINESE is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DOSAGE AND ADMINISTRATION

There is no fixed dosage regimen for the management of type 2 diabetes with DIABINESE or any other hypoglycemic agent. The patient's blood glucose must be monitored periodically to determine the minimum effective dose for the patient to detect primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication and to detect secondary failure, i.e., loss of an adequate blood glucose lowering response after an initial period of effectiveness. Glycosylated hemoglobin levels may also be of value in monitoring the patient's response to therapy. Short-term administration of DIABINESE may be sufficient during periods of transient loss of control in patients usually controlled well on diet. The total daily dosage is generally taken at a single time each morning with breakfast. Occasionally cases of gastrointestinal intolerance may be relieved by dividing the daily dosage. A LOADING OR PRIMING DOSE IS NOT NECESSARY AND SHOULD NOT BE USED.
Initial Therapy

1. The mild to moderately severe, middle-aged, stable type 2 diabetes patient should be started on 250 mg daily. In elderly patients, debilitated or malnourished patients, and patients with impaired renal or hepatic function, the initial and maintenance dosing should be conservative to avoid hypoglycemic reactions (see PRECAUTIONS section). Older patients should be started on smaller amounts of DIABINESE, in the range of 100 to 125 mg daily.
2. No transition period is necessary when transferring patients from other oral hypoglycemic agents to DIABINESE. The other agent may be discontinued abruptly and chlorpropamide started at once. In prescribing chlorpropamide, due consideration must be given to its greater potency.

Many mild to moderately severe, middle-aged, stable type 2 diabetes patients receiving insulin can be placed directly on the oral drug and their insulin abruptly discontinued. For patients requiring more than 40 units of insulin daily, therapy with DIABINESE may be initiated with a 50 per cent reduction in insulin for the first few days, with subsequent further reductions dependent upon the response. During the initial period of therapy with chlorpropamide, hypoglycemic reactions may occasionally occur, particularly during the transition from insulin to the oral drug. Hypoglycemia within 24 hours after withdrawal of the intermediate or long-acting types of insulin will usually prove to be the result of insulin carry-over and not primarily due to the effect of chlorpropamide.

During the insulin withdrawal period, the patient should self-monitor glucose levels at least three times daily. If they are abnormal, the physician should be notified immediately. In some cases, it may be advisable to consider hospitalization during the transition period. Five to seven days after the initial therapy, the blood level of chlorpropamide reaches a plateau. Dosage may subsequently be adjusted upward or downward by increments of not more than 50 to l25 mg at intervals of three to five days to obtain optimal control. More frequent adjustments are usually undesirable.
Maintenance Therapy

Most moderately severe, middle-aged, stable type 2 diabetes patients are controlled by approximately 250 mg daily. Many investigators have found that some milder diabetics do well on daily doses of 100 mg or less. Many of the more severe diabetics may require 500 mg daily for adequate control. PATIENTS WHO DO NOT RESPOND COMPLETELY TO 500 MG DAILY WILL USUALLY NOT RESPOND TO HIGHER DOSES. MAINTENANCE DOSES ABOVE 750 mg DAILY SHOULD BE AVOIDED.

SIDE EFFECTS
Body as a Whole

Disulfiram-like reactions have rarely been reported with DIABINESE (see DRUG INTERACTIONS).
Central and Peripheral Nervous System

Dizziness and headache.
Hypoglycemia

See PRECAUTIONS and OVERDOSAGE sections.
Gastrointestinal

Gastrointestinal disturbances are the most common reactions nausea has been reported in less than 5% of patients, and diarrhea, vomiting, anorexia, and hunger in less than 2%. Other gastrointestinal disturbances have occurred in less than 1% of patients including proctoco